Last reviewed · How we verify

Shandong Luye Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Shandong Luye Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
an extract of Cimicifuga Foetida L. an extract of Cimicifuga Foetida L. marketed Herbal extract / phytoestrogen Women's Health / Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Federal University of Minas Gerais · 1 shared drug class
  2. Phytopharm Consulting Brazil · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shandong Luye Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shandong Luye Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shandong-luye-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related